Evidence map›Paper›PMID 26085169›Full record

ArticleJournal of virology2015

Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.

N Oreshkova, L Spel, R P M Vloet, P J Wichgers Schreur, R J M Moormann, M Boes, J Kortekaas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Arboviruses in Cancer therapy: pros and cons.Journal of neurovirology · 2026
    Review
  2. Review
  3. Viral Replicon Systems and Their Biosafety Aspects.Applied biosafety : journal of the American Biological Safety Association · 2023
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

N OreshkovaDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
L SpelDepartment of Pediatric Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
R P M VloetDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands.
P J Wichgers SchreurDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands.
R J M MoormannDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands Department of Infectious Diseases and Immunology, Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
M BoesDepartment of Pediatric Immunology and Laboratory of Translational Immunology, University Medical Center Utrecht/Wilhelmina Children's Hospital, Utrecht, The Netherlands.
J KortekaasDepartment of Virology, Central Veterinary Institute, part of Wageningen University and Research Centre, Lelystad, The Netherlands jeroen.kortekaas@wur.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8(+) T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.

Indexed as

AnimalsCancer VaccinesCD8-Positive T-LymphocytesDendritic CellsEpitopesHumansImmunotherapyLymphocyte ActivationLymphomaMiceMice, Inbred C57BLPhosphoproteinsRift Valley fever virusVaccinationViral Matrix ProteinsCancer Vaccinescytomegalovirus matrix protein 65kDaEpitopesPhosphoproteinsViral Matrix Proteins

Identifiers

PMID26085169
PMCPMC4524072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.